Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1.

MLA

Wallen, Zachary D., et al. “Genomic Profiling of NSCLC Tumors with the TruSight Oncology 500 Assay Provides Broad Coverage of Clinically Actionable Genomic Alterations and Detection of Known and Novel Associations between Genomic Alterations, TMB, and PD-L1.” Frontiers in Oncology, Dec. 2024, pp. 1–15. EBSCOhost, https://doi.org/10.3389/fonc.2024.1473327.

APA

Wallen, Z. D., Nesline, M. K., Tierno, M., Roos, A., Schnettler, E., Husain, H., Sathyan, P., Caveney, B., Eisenberg, M., Severson, E. A., & Ramkissoon, S. H. (2024). Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1. Frontiers in Oncology, 1–15. https://doi.org/10.3389/fonc.2024.1473327

Chicago

Wallen, Zachary D., Mary K. Nesline, Marni Tierno, Alison Roos, Erica Schnettler, Hatim Husain, Pratheesh Sathyan, et al. 2024. “Genomic Profiling of NSCLC Tumors with the TruSight Oncology 500 Assay Provides Broad Coverage of Clinically Actionable Genomic Alterations and Detection of Known and Novel Associations between Genomic Alterations, TMB, and PD-L1.” Frontiers in Oncology, December, 1–15. doi:10.3389/fonc.2024.1473327.